Anxiety disorders are a prevalent and disabling condition. Because of high rates of treatment resistance, there is interest in new pharmacological treatment options such as second-generation antipsychotics. This systematic review evaluated the efficacy and tolerability of second-generation antipsychotics in the treatment of anxiety disorders. We found eleven randomised placebo-controlled trials, comparing quetiapine, olanzapine and risperidone with placebo and antidepressants. The vast majority of the available data was on quetiapine (> 3000 participants). Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo, measured as a reduction in the Hamilton Anxiety Scale (HAM-A). Participants treated with quetiapine were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. The evidence on the other second-generation antipsychotics is currently too limited to draw any conclusions.
- Going to extremes for one’s group: the role of prototypicality and group acceptance
- Patient and family member perspectives on searching for cancer clinical trials: A qualitative interview study
- Development of a multi-target contingency management intervention for HIV positive substance users
- Identifying and Addressing the Unmet Health Care Needs of Drug Court Clients
- Impulsivity is associated with blood pressure and waist circumference among adolescents with bipolar disorder
Category Specific RSS